Sinil Pharmaceutical Co. Ltd (012790) - Net Assets
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has net assets worth ₩151.71 Billion KRW (≈ $102.81 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩169.94 Billion ≈ $115.16 Million USD) and total liabilities (₩18.23 Billion ≈ $12.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sinil Pharmaceutical Co. Ltd (012790) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩151.71 Billion |
| % of Total Assets | 89.27% |
| Annual Growth Rate | 7.53% |
| 5-Year Change | 36.3% |
| 10-Year Change | 87.41% |
| Growth Volatility | 2.39 |
Sinil Pharmaceutical Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 012790 total assets for the complete picture of this company's asset base.
Annual Net Assets for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual net assets of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. For live valuation and market cap data, see 012790 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩146.51 Billion ≈ $99.28 Million |
+8.61% |
| 2023-12-31 | ₩134.90 Billion ≈ $91.42 Million |
+9.42% |
| 2022-12-31 | ₩123.28 Billion ≈ $83.54 Million |
+8.91% |
| 2021-12-31 | ₩113.20 Billion ≈ $76.71 Million |
+5.31% |
| 2020-12-31 | ₩107.48 Billion ≈ $72.84 Million |
+6.16% |
| 2019-12-31 | ₩101.24 Billion ≈ $68.61 Million |
+6.37% |
| 2018-12-31 | ₩95.18 Billion ≈ $64.51 Million |
+4.68% |
| 2017-12-31 | ₩90.93 Billion ≈ $61.62 Million |
+4.29% |
| 2016-12-31 | ₩87.19 Billion ≈ $59.09 Million |
+11.53% |
| 2015-12-31 | ₩78.17 Billion ≈ $52.98 Million |
+10.33% |
| 2014-12-31 | ₩70.85 Billion ≈ $48.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sinil Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 112.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩140.44 Billion | 95.86% |
| Common Stock | ₩5.99 Billion | 4.09% |
| Other Components | ₩68.82 Million | 0.05% |
| Total Equity | ₩146.51 Billion | 100.00% |
Sinil Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aether Holdings, Inc.
NASDAQ:ATHR
|
$49.20 Million |
|
PetMed Express Inc
NASDAQ:PETS
|
$49.22 Million |
|
Samebest Co Ltd
TWO:8489
|
$49.23 Million |
|
Fonet Bilgi Teknolojileri AS
IS:FONET
|
$49.23 Million |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
$49.18 Million |
|
Mildex Optical
TWO:4729
|
$49.17 Million |
|
Bowler Metcalf Ltd
JSE:BCF
|
$49.16 Million |
|
Ymc Co. Ltd
KQ:155650
|
$49.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinil Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 134,895,027,290 to 146,505,712,280, a change of 11,610,684,990 (8.6%).
- Net income of 14,300,644,570 contributed positively to equity growth.
- Dividend payments of 1,965,125,370 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩14.30 Billion | +9.76% |
| Dividends Paid | ₩1.97 Billion | -1.34% |
| Other Changes | ₩-724.83 Million | -0.49% |
| Total Change | ₩- | 8.61% |
Book Value vs Market Value Analysis
This analysis compares Sinil Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.80x to 0.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩7822.00 | ₩6280.00 | x |
| 2017-12-31 | ₩8157.55 | ₩6280.00 | x |
| 2018-12-31 | ₩8539.16 | ₩6280.00 | x |
| 2019-12-31 | ₩9082.81 | ₩6280.00 | x |
| 2020-12-31 | ₩9643.22 | ₩6280.00 | x |
| 2021-12-31 | ₩10069.36 | ₩6280.00 | x |
| 2022-12-31 | ₩11082.32 | ₩6280.00 | x |
| 2023-12-31 | ₩11669.56 | ₩6280.00 | x |
| 2024-12-31 | ₩12673.99 | ₩6280.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinil Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.76%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.99%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.13x
- Recent ROE (9.76%) is above the historical average (9.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 14.37% | 21.14% | 0.60x | 1.13x | ₩3.09 Billion |
| 2015 | 11.21% | 19.60% | 0.51x | 1.12x | ₩946.19 Million |
| 2016 | 11.51% | 19.99% | 0.51x | 1.12x | ₩1.32 Billion |
| 2017 | 9.02% | 16.09% | 0.50x | 1.13x | ₩-894.97 Million |
| 2018 | 6.00% | 10.72% | 0.50x | 1.12x | ₩-3.80 Billion |
| 2019 | 7.17% | 11.97% | 0.51x | 1.16x | ₩-2.87 Billion |
| 2020 | 7.02% | 12.28% | 0.49x | 1.16x | ₩-3.20 Billion |
| 2021 | 5.90% | 10.82% | 0.48x | 1.14x | ₩-4.64 Billion |
| 2022 | 9.86% | 15.20% | 0.56x | 1.16x | ₩-170.65 Million |
| 2023 | 10.11% | 15.30% | 0.58x | 1.13x | ₩151.85 Million |
| 2024 | 9.76% | 15.99% | 0.54x | 1.13x | ₩-349.93 Million |
Industry Comparison
This section compares Sinil Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinil Pharmaceutical Co. Ltd (012790) | ₩151.71 Billion | 14.37% | 0.12x | $49.20 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more